Q32 Bio (QTTB) to Release Quarterly Earnings on Tuesday

Q32 Bio (NASDAQ:QTTB) is expected to announce its earnings results before the market opens on Tuesday, March 11th. Analysts expect the company to announce earnings of ($1.25) per share for the quarter.

Q32 Bio Trading Down 4.8 %

NASDAQ:QTTB opened at $2.16 on Tuesday. Q32 Bio has a 1-year low of $2.13 and a 1-year high of $53.79. The business’s 50-day moving average price is $3.07 and its two-hundred day moving average price is $25.14. The firm has a market capitalization of $26.31 million, a price-to-earnings ratio of -0.15 and a beta of -0.32. The company has a current ratio of 6.53, a quick ratio of 6.53 and a debt-to-equity ratio of 0.61.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on QTTB shares. Leerink Partners restated a “market perform” rating and issued a $9.00 price target (down from $68.00) on shares of Q32 Bio in a report on Wednesday, December 11th. Leerink Partnrs downgraded Q32 Bio from a “strong-buy” rating to a “hold” rating in a report on Wednesday, December 11th. Wells Fargo & Company restated an “equal weight” rating and issued a $16.00 price target (down from $95.00) on shares of Q32 Bio in a report on Wednesday, December 11th. Guggenheim downgraded Q32 Bio from a “buy” rating to a “neutral” rating in a report on Wednesday, December 11th. Finally, BMO Capital Markets downgraded Q32 Bio from an “outperform” rating to a “market perform” rating and lowered their price target for the stock from $22.00 to $3.00 in a report on Tuesday, February 11th. Six analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to MarketBeat.com, Q32 Bio has a consensus rating of “Hold” and a consensus target price of $24.86.

Q32 Bio Company Profile

Q32 Bio Inc, a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis.